|
Video: What is a Stock Split?
|
|
Cullinan Oncology is a biopharmaceutical company. Zipalertinib (CLN-081/TAS6417) which Co. is co-developing with an affiliate of Taiho Pharmaceutical, Co. Ltd (Taiho), is an orally bioavailable small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor that is designed to selectively target cells expressing EGFR exon 20 insertion (EGFRex20ins) mutations with relative sparing of cells expressing wild-type EGFR. In addition to zipalertinib, Co.'s portfolio includes four other clinical-stage product candidates and one product candidate that is pending the U.S. Food and Drug Administration clearance for its investigational new drug application. According to our Cullinan Therapeutics stock split history records, Cullinan Therapeutics has had 0 splits. | |
|
Cullinan Therapeutics (CGEM) has 0 splits in our Cullinan Therapeutics stock split history database.
Looking at the Cullinan Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cullinan Therapeutics shares, starting with a $10,000 purchase of CGEM, presented on a split-history-adjusted basis factoring in the complete Cullinan Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/11/2021 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$28.00 |
|
End price/share: |
$16.67 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-40.46% |
|
Average Annual Total Return: |
-14.63% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,952.77 |
|
Years: |
3.28 |
|
|
|
|
|